Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Blake

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|May 19, 2009
Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitorsRobert T Hendricks, Jay B Fell, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2011
Discovery and SAR of spirochromane Akt inhibitorsNicholas C Kallan, Keith L Spencer, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2010
Discovery of pyrrolopyrimidine inhibitors of AktJames F Blake, Nicholas C Kallan, Dengming Xiao, et al.
Journal of Medicinal Chemistry|January 21, 2015
Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2Li Ren, Jonas Grina, David Moreno, et al.
JCO Precision Oncology|September 14, 2020
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered CancerLori J Wirth, Takashi Kohno, Hibiki Udagawa, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2011
Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKARui Xu, Anna Banka, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2010
Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitorsJosef R Bencsik, Dengming Xiao, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2014
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2James F Blake, John J Gaudino, Jason De Meese, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 InhibitorsMohamed S A Elsayed, James F Blake, Mark L Boys, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|May 19, 2009
Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitorsRobert T Hendricks, Jay B Fell, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2011
Discovery and SAR of spirochromane Akt inhibitorsNicholas C Kallan, Keith L Spencer, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2010
Discovery of pyrrolopyrimidine inhibitors of AktJames F Blake, Nicholas C Kallan, Dengming Xiao, et al.
Journal of Medicinal Chemistry|January 21, 2015
Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2Li Ren, Jonas Grina, David Moreno, et al.
JCO Precision Oncology|September 14, 2020
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered CancerLori J Wirth, Takashi Kohno, Hibiki Udagawa, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2011
Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKARui Xu, Anna Banka, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2010
Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitorsJosef R Bencsik, Dengming Xiao, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2014
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2James F Blake, John J Gaudino, Jason De Meese, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 InhibitorsMohamed S A Elsayed, James F Blake, Mark L Boys, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
Pageof 3